{"id":"NCT01716104","sponsor":"Materia Medica Holding","briefTitle":"Clinical Trial of Safety and Efficacy of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression","officialTitle":"Multicentric Double-blind Placebo-controlled Randomized Parallel-group Clinical Trial of Safety and Efficacy of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-11","primaryCompletion":"2016-11","completion":"2016-11","firstPosted":"2012-10-29","resultsPosted":"2018-10-09","lastUpdate":"2018-11-28"},"enrollment":260,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Benign Prostatic Hyperplasia"],"interventions":[{"type":"DRUG","name":"Afalaza","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Afalaza (2 tablets twice a day)","type":"EXPERIMENTAL"},{"label":"Placebo (2 tablets twice a day)","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is:\n\n* To assess safety of Afalaza drug within 12 months in patients with symptoms of benign prostatic hyperplasia (BPH) and risk of progression.\n* To assess efficacy of Afalaza drug within 12 months in patients with symptoms of benign prostatic hyperplasia and risk of progression.","primaryOutcome":{"measure":"Change in Total IPSS Scores (International Prostate Symptome Score) After 1, 3, 6 and 12 Months Compared to Baseline.","timeFrame":"Baseline, 1, 3, 6 and 12 months","effectByArm":[{"arm":"Afalaza","deltaMin":-1.3,"sd":1.7},{"arm":"Placebo","deltaMin":-0.6,"sd":1.3}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0005"}]},"eligibility":{"minAge":"45 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":16,"countries":["Russia","Ukraine"]},"refs":{"pmids":["30680237"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":125},"commonTop":["Acute respiratory viral infection","Prostatic specific antigen increased","Headache","Nausea","Rhinitis"]}}